Тактика подбора АнтикоАГУлянтной терапии у пациентов с фибрилляцией предсердий и ишемической болезнью сердца

В клинической практике лечащий врач нередко теряется в «свободе выбора», предоставляемой ему прямыми пероральными антикоагулянтами. Если пациенту с неклапанной фибрилляцией предсердий показана антикоагулянтная терапия, то какому препарату отдать предпочтение? Какие преимущества получит пациент с ишемической болезнью сердца и фибрилляцией предсердий от назначения определенных прямых пероральных антикоагулянтов и какие риски несет за собой такая терапия? На все эти вопросы в статье даются ответы.

фибрилляция предсердий, ишемическая болезнь сердца, острый коронарный синдром, прямые пероральные антикоагулянты, ривароксабан, апиксабан, дабигатран, atrial fibrillation, ischemic heart disease, acute coronary syndrome, direct oral anticoagulants, rivaroxaban, apixaban, dabigatran

1. January C. T., Wann L. S., Alpert J. S. et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol 2014. DOI: 10.1016/j. jacc. 2014.03.022.

2. Turakhia M., Solomon M. D., Jhaveri M. et al. Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation. Am Heart J 2013;166:573-580.

3. Kirchhof P., Auricchio A., Bax J. et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007;28:2803-2817.

4. Kakkar A. K., Mueller I., Bassand J.-P. et al. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLOS ONE 2013;8 (5):e63479.

5. Camm A.J., Kirchhof P., Lip G. Y. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31 (19):2369-2429. doi: 10.1093/eur-heartj/ehq278.

6. Olesen J. B. Lip G. Y., Hansen M. L. et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342: d124. doi: https://doi.org/10.1136/bmj. d124.

7. Soliman E. Z., Safford M. M., Muntner P. et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 2013;174 (1): 107-114. doi: 10.1001 /jamainternmed. 2013.11912.

8. Soliman E. Z., Lopez F., O'Neal W. T. et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: the atherosclerosis risk in communities (ARIC) study. Circulation 2016;131 (21):1843-1850. doi: 10.1161/CIRCULATIONAHA. 114.014145.

9. Polimeni L., Perri L., Saliola M. et al. The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. Intern Emerg Med 2010; 5 (2):91-94. doi:10.1007/s11739-010-0352-2.

10. Pastori D., Farcomeni A., Poli D. et al. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Intern Emerg Med 2016;11:199-204. DOI 10.1007/s11739-015-1326-1.

11. Fox K. A., Eagle K. A., Gore J. M. et al. The Global Registry of Acute Coronary Events, 1999 to 2009 - GRACE. Heart 2010;96:1095-1101.

12. Healey J., Oldgren J., Parekh A. et al. Global variations in the 1-year rates of death and stroke in 15,432 patients presenting to the emergency department with atrial fibrillation in 47 countries: The RE-LY AF Registry; 2012; Munich, Germany.

13. Piccini J. P., Holmes D. N., Ollis D. M. et al. Patterns of atrial fibrillation and treatment trategies vary according to provider specialty across community practice settings: findings from the ORBIT-AF Registry. Circulation 2011;124: A16415.

14. Patel M. R., Mahaffey K. W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.

15. Connolly S.J., Ezekowitz M. D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.

16. Connolly S. J., Ezekowitz M. D., Yusuf S. et al. Randomized evaluation of long-term anticoagulation therapy investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-1876.

17. Hohnloser S. H., Oldgren J., Yang S. et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY Trial. Circulation 2012;125:669-676.

18. Uchino K., Hernandez A. V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172 (5):397-402.

19. Turpie A. G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscl Thromb Vasc Biol 2007;27:1238-1247.

20. Artang R., Rome E., Nielsen J. D., Vidaillet H.J. Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors. Am J Cardiol 2013;112:1973-1979.

21. Hurlen M., Abdelnoor M., Smith P. et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-974.

22. Mak K.-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open 2012;2: e001592.

23. Tornyos A., Kehl D., Ascenzo D. F., Komocsi A. Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. Progress in cardiovascular diseases 2016; 58: 483-494.

24. Mega J. L. Braunwald E., Murphy S. A. et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol 2013;61 (18):1853-1859. doi: 10.1016/j. jacc. 2013.01.066.

25. Oldgren J., Budaj A., Granger C. B. et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32 (22):2781-2789.doi: 10.1093/eurheartj/ehr113.Epub 2011 May 7.

26. Alexander J. H., Lopes R. D., James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365 (8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011Jul 24.

27. Gibson M. C., Mehran R., Bode C. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016;375:2423-2434. doi: 10.1056/NEJMoa1611594.

28. Cannon C. P. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; doi: 10.1056/NEJMoa1708454

29. Valgimigli M., Bueno H., Byrne R. A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2017 Aug 26. doi: 10.1093/eurheartj/ehx419.